ASND Ascendis Pharma A/S
- 125.770
- +0.490+0.39%
- 125.770
- 0.0000.00%
Ascendis Pharma A/S News
Cantor Fitzgerald Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $170
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Ascendis Pharma (ASND) Receives a Buy From Cantor Fitzgerald
Ascendant Resources Analyst Ratings
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $191
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $191
J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $174
Ascendis Pharma Is Maintained at Buy by TD Cowen
Ascendis Pharma Analyst Ratings
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
TD Cowen Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $160
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Ascendis Pharma Analyst Ratings
B of A Securities Maintains Buy on Ascendis Pharma, Raises Price Target to $191
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $191
Cantor Fitzgerald Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $205
Analysis
Price Target
No Data
No Data